BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27612171)

  • 1. The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer.
    Fleckenstein J; Jelden M; Kremp S; Jagoda P; Stroeder J; Khreish F; Ezziddin S; Buecker A; Rübe C; Schneider GK
    PLoS One; 2016; 11(9):e0162816. PubMed ID: 27612171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MRI of the lung at 3T evaluated using echo-planar-based and single-shot turbo spin-echo-based acquisition techniques for radiotherapy applications.
    Tyagi N; Cloutier M; Zakian K; Deasy JO; Hunt M; Rimner A
    J Appl Clin Med Phys; 2019 Jan; 20(1):284-292. PubMed ID: 30421496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating diffusion-weighted magnetic resonance imaging for target volume delineation in head and neck radiotherapy.
    Cardoso M; Min M; Jameson M; Tang S; Rumley C; Fowler A; Estall V; Pogson E; Holloway L; Forstner D
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):399-407. PubMed ID: 30816646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC.
    Jagoda P; Fleckenstein J; Sonnhoff M; Schneider G; Ruebe C; Buecker A; Stroeder J
    Cancer Imaging; 2021 Jan; 21(1):15. PubMed ID: 33478592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
    Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gross tumour volume delineation in anal cancer on T2-weighted and diffusion-weighted MRI - Reproducibility between radiologists and radiation oncologists and impact of reader experience level and DWI image quality.
    Min LA; Vacher YJL; Dewit L; Donker M; Sofia C; van Triest B; Bos P; van Griethuysen JJW; Maas M; Beets-Tan RGH; Lambregts DMJ
    Radiother Oncol; 2020 Sep; 150():81-88. PubMed ID: 32540336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
    Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515.
    Bradley J; Bae K; Choi N; Forster K; Siegel BA; Brunetti J; Purdy J; Faria S; Vu T; Thorstad W; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):435-41.e1. PubMed ID: 21075551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
    Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
    Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
    Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
    J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.